Global NewsNews

Gland Pharma inks pact with RDIF

To supply 252 million doses of Sputnik V COVID-19 vaccine

Drug firm Gland Pharma has entered into an agreement with the Russian Direct Investment Fund (RDIF) to supply up to 252 million doses of Sputnik V COVID-19 vaccine.

The company “will be leveraging its manufacturing capabilities for the production of Sputnik V Covid-19 vaccine,” Gland Pharma said in a regulatory filing.

The agreement will see the company utilising its Drug Substance and Drug Product facilities at its sites in Hyderabad. The production is expected to commence from the third quarter of 2021 for estimated delivery starting from the fourth quarter of 2021, it added.

“Under the terms of the agreement, Gland Pharma will first undertake technology transfer of the drug substance to its manufacturing facilities,” the filing said.

After successful technology transfer, the company will then undertake manufacturing of drug substance and drug product filling into vials under aseptic conditions, it added.

The company’s expertise in manufacturing sterile injectables at a significant scale will support in establishing a stable supply of COVID-19 vaccine, Gland Pharma said.


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button